| Date Filed | Type | Description |
| 06/16/2023 |
4
| Gujrathi Sheila (Director) has filed a Form 4 on Janux Therapeutics, Inc.|
Txns:
| Granted 12,500 options to buy
@ $13.22, valued at
$165.3k
|
|
| 06/12/2023 |
4
| Gujrathi Sheila (Director) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Granted 15,937 options to buy
@ $34.83, valued at
$555.1k
|
|
| 04/26/2023 |
4/A
| Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] |
| 03/31/2023 |
4
| Gujrathi Sheila (Director) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Sold 100,000 shares
@ $33.7324, valued at
$3.4M
Exercised 100,000 options to buy
@ $6.03, valued at
$603k
|
|
| 02/13/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/10/2022 |
4
| Gujrathi Sheila (Director) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Granted 13,301 options to buy
@ $16.54, valued at
$220k
|
|
| 12/03/2021 |
4
| Gujrathi Sheila (Director) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Granted 277,941 options to buy
@ $18.65, valued at
$5.2M
|
|
| 10/25/2021 |
4
| Gujrathi Sheila (Director) has filed a Form 4 on Ventyx Biosciences, Inc.|
Txns:
| Converted 32,897 shares
@ $0
Converted 32,897 preferred shares
@ $0 |
|
| 10/20/2021 |
3
| Gujrathi Sheila (Director) has filed a Form 3 on Ventyx Biosciences, Inc. |
| 06/10/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 02/12/2021 |
SC 13G
| Gossamer Bio, Inc. reports a 4.8% stake in GOSSAMER BIO, INC. |
| 06/17/2020 |
4
| Gujrathi Sheila (Director) has filed a Form 4 on Turning Point Therapeutics, Inc.|
Txns:
| Granted 8,500 options to buy
@ $65.39, valued at
$555.8k
|
|
| 02/19/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/10/2020 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 09/27/2019 |
4
| Gujrathi Sheila (President & CEO) has filed a Form 4 on Gossamer Bio, Inc.|
Txns:
| Bought 10,000 shares
@ $16.798, valued at
$168k
|
|
| 04/24/2019 |
4
| Gujrathi Sheila (Director) has filed a Form 4 on Turning Point Therapeutics, Inc.|
Txns:
| Granted 15,000 options to buy
@ $27.06, valued at
$405.9k
|
|
| 04/16/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 03/26/2019 |
4
| Gujrathi Sheila (President & CEO) has filed a Form 4 on Gossamer Bio, Inc.|
Txns:
| Granted 380,000 options to buy
@ $22.1, valued at
$8.4M
|
|
| 02/12/2019 |
4
| Gujrathi Sheila (President & CEO) has filed a Form 4 on Gossamer Bio, Inc.|
Txns:
| Converted 62,030 shares
@ $0
Converted 223,182 preferred shares
@ $0
Converted 55,957 preferred shares
@ $0 |
|
| 02/07/2019 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 05/14/2018 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/12/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 05/23/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/19/2013 |
4
| Gujrathi Sheila (Chief Medical Officer) has filed a Form 4 on Receptos, Inc.|
Txns:
| Granted 129,400 options to buy
@ $18.77, valued at
$2.4M
|
|
| 05/08/2013 |
3
| Gujrathi Sheila (Chief Medical Officer) has filed a Form 3 on Receptos, Inc. |